Evaluation of pharmacological treatment strategies in traumatic brain injury
Marklund, Niklas LU
; Bakshi, Asha
; Castelbuono, Deborah J
; Conte, Valeria
and McIntosh, Tracy K
(2006)
In Current Pharmaceutical Design
12(13).
p.80-1645
- Abstract
Traumatic brain injury (TBI) is a devastating disease, predominately affecting young people. Although the prognosis for TBI victims has improved in recent years, many survivors of TBI suffer from emotional, cognitive and motor disturbances and a decreased quality of life. In recent years, there has been a rapid increase in the number of pharmacological targets evaluated in clinically-relevant experimental TBI models, showing improved cognitive and motor outcome and decreased loss of brain tissue. Despite the completion of several recent clinical trials using compounds showing neuroprotection in preclinical studies, pharmaceutical treatment strategies with proven clinical benefit are still lacking. This paper reviews the preclinical... (More)
Traumatic brain injury (TBI) is a devastating disease, predominately affecting young people. Although the prognosis for TBI victims has improved in recent years, many survivors of TBI suffer from emotional, cognitive and motor disturbances and a decreased quality of life. In recent years, there has been a rapid increase in the number of pharmacological targets evaluated in clinically-relevant experimental TBI models, showing improved cognitive and motor outcome and decreased loss of brain tissue. Despite the completion of several recent clinical trials using compounds showing neuroprotection in preclinical studies, pharmaceutical treatment strategies with proven clinical benefit are still lacking. This paper reviews the preclinical pharmacological treatment studies evaluated to date in experimental models of TBI. Although human TBI is a complex and multifaceted disease, these studies provide encouraging translational data suggesting that pharmacological compounds, delivered in a clinically-relevant time window, may improve the outcome of TBI patients.
(Less)
- author
- Marklund, Niklas
LU
; Bakshi, Asha
; Castelbuono, Deborah J
; Conte, Valeria
and McIntosh, Tracy K
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- keywords
- Animals, Anti-Inflammatory Agents, Brain Injuries, Calcium Channel Blockers, Calpain, Caspase Inhibitors, Excitatory Amino Acid Antagonists, Humans, Nerve Growth Factors, Nitric Oxide Synthase, Reactive Nitrogen Species, Reactive Oxygen Species, Receptors, N-Methyl-D-Aspartate, Synaptic Transmission, Journal Article, Review
- in
- Current Pharmaceutical Design
- volume
- 12
- issue
- 13
- pages
- 80 - 1645
- publisher
- Bentham Science Publishers
- external identifiers
-
- pmid:16729876
- scopus:33646516853
- ISSN
- 1381-6128
- language
- English
- LU publication?
- no
- id
- 9d6fa0b1-8ec2-4566-a8c0-3376e5207588
- date added to LUP
- 2018-03-03 14:25:31
- date last changed
- 2024-04-01 01:54:55
@article{9d6fa0b1-8ec2-4566-a8c0-3376e5207588,
abstract = {{<p>Traumatic brain injury (TBI) is a devastating disease, predominately affecting young people. Although the prognosis for TBI victims has improved in recent years, many survivors of TBI suffer from emotional, cognitive and motor disturbances and a decreased quality of life. In recent years, there has been a rapid increase in the number of pharmacological targets evaluated in clinically-relevant experimental TBI models, showing improved cognitive and motor outcome and decreased loss of brain tissue. Despite the completion of several recent clinical trials using compounds showing neuroprotection in preclinical studies, pharmaceutical treatment strategies with proven clinical benefit are still lacking. This paper reviews the preclinical pharmacological treatment studies evaluated to date in experimental models of TBI. Although human TBI is a complex and multifaceted disease, these studies provide encouraging translational data suggesting that pharmacological compounds, delivered in a clinically-relevant time window, may improve the outcome of TBI patients.</p>}},
author = {{Marklund, Niklas and Bakshi, Asha and Castelbuono, Deborah J and Conte, Valeria and McIntosh, Tracy K}},
issn = {{1381-6128}},
keywords = {{Animals; Anti-Inflammatory Agents; Brain Injuries; Calcium Channel Blockers; Calpain; Caspase Inhibitors; Excitatory Amino Acid Antagonists; Humans; Nerve Growth Factors; Nitric Oxide Synthase; Reactive Nitrogen Species; Reactive Oxygen Species; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission; Journal Article; Review}},
language = {{eng}},
number = {{13}},
pages = {{80--1645}},
publisher = {{Bentham Science Publishers}},
series = {{Current Pharmaceutical Design}},
title = {{Evaluation of pharmacological treatment strategies in traumatic brain injury}},
volume = {{12}},
year = {{2006}},
}